HC Wainwright reaffirmed their buy rating on shares of REGENXBIO (NASDAQ:RGNX - Free Report) in a report released on Tuesday,Benzinga reports. The firm currently has a $34.00 price target on the biotechnology company's stock.
Several other brokerages have also issued reports on RGNX. Royal Bank Of Canada cut their target price on REGENXBIO from $21.00 to $17.00 and set an "outperform" rating for the company in a research note on Friday, August 8th. Barclays dropped their price objective on REGENXBIO from $50.00 to $37.00 and set an "overweight" rating for the company in a research note on Friday, August 8th. Chardan Capital reissued a "buy" rating and set a $52.00 price objective on shares of REGENXBIO in a research note on Friday, August 8th. Finally, Wall Street Zen lowered REGENXBIO from a "hold" rating to a "strong sell" rating in a research note on Saturday, August 9th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $28.38.
Read Our Latest Report on REGENXBIO
REGENXBIO Stock Performance
RGNX traded up $0.90 during midday trading on Tuesday, hitting $9.01. The stock had a trading volume of 1,355,248 shares, compared to its average volume of 680,725. The company has a market cap of $455.10 million, a P/E ratio of -2.62 and a beta of 1.11. The business has a fifty day moving average of $8.52 and a 200 day moving average of $8.07. REGENXBIO has a 1 year low of $5.03 and a 1 year high of $13.48.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.13) by ($0.25). The firm had revenue of $21.36 million during the quarter, compared to analysts' expectations of $40.87 million. REGENXBIO had a negative return on equity of 66.95% and a negative net margin of 112.70%. On average, equities research analysts anticipate that REGENXBIO will post -4.84 earnings per share for the current year.
Institutional Trading of REGENXBIO
A number of institutional investors and hedge funds have recently added to or reduced their stakes in RGNX. Price T Rowe Associates Inc. MD boosted its position in REGENXBIO by 9.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 23,910 shares of the biotechnology company's stock worth $185,000 after purchasing an additional 1,982 shares during the last quarter. Pale Fire Capital SE lifted its position in shares of REGENXBIO by 7.7% during the 2nd quarter. Pale Fire Capital SE now owns 27,846 shares of the biotechnology company's stock valued at $229,000 after buying an additional 2,000 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of REGENXBIO by 9.1% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 27,756 shares of the biotechnology company's stock valued at $198,000 after buying an additional 2,326 shares in the last quarter. ProShare Advisors LLC lifted its position in shares of REGENXBIO by 22.4% during the 4th quarter. ProShare Advisors LLC now owns 15,314 shares of the biotechnology company's stock valued at $118,000 after buying an additional 2,800 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of REGENXBIO by 2.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 100,452 shares of the biotechnology company's stock valued at $775,000 after buying an additional 2,827 shares in the last quarter. Hedge funds and other institutional investors own 88.08% of the company's stock.
REGENXBIO Company Profile
(
Get Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Read More
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
